EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juvenile idiopathic arth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• TYENNE (TOCILIZUMAB-AAZG)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Cytokine Release Syndrome;Arthritis, Juvenile Rheumatoid;COVID-19 virus infection;Giant Cell Arteritis. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 18/08/2026